These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 29103180

  • 1. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
    Correll CK, Bullock DR, Cafferty RM, Vehe RK.
    Clin Rheumatol; 2018 Feb; 37(2):549-553. PubMed ID: 29103180
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
    Cecchin V, Zannin ME, Ferrari D, Pontikaki I, Miserocchi E, Paroli MP, Bracaglia C, Marafon DP, Pastore S, Parentin F, Simonini G, De Libero C, Falcini F, Petaccia A, Filocamo G, De Marco R, La Torre F, Guerriero S, Martino S, Comacchio F, Muratore V, Martini G, Vittadello F, Zulian F.
    J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Uveitis as predictor of disease flare after the first anti-TNF withdrawal in oligoarticular and polyarticular juvenile idiopathic arthritis: a multicentric Italian experience.
    Maccora I, Accardo V, Cattalini M, Pagnini I, Taddio A, Marrani E, La Torre F, Mastrolia MV, Bellicini I, Pastore S, Simonini G.
    Clin Exp Rheumatol; 2024 Sep; 42(9):1867-1875. PubMed ID: 38976296
    [Abstract] [Full Text] [Related]

  • 8. Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data.
    Nassar-Sheikh Rashid A, Hooijberg F, Bergkamp SC, Gruppen MP, Kuijpers TW, Nurmohamed M, Rispens T, Wolbink G, van den Berg JM, Schonenberg-Meinema D, Mathôt RAA.
    Paediatr Drugs; 2024 Jul; 26(4):441-450. PubMed ID: 38630199
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.
    Hughes DA, Culeddu G, Plumpton CO, Wood E, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot Lacassagne S, Hardwick B, Hickey H, Woo P, Beresford MW, Ramanan AV.
    Ophthalmology; 2019 Mar; 126(3):415-424. PubMed ID: 30336181
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.
    Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J.
    Arch Dis Child; 2019 Mar; 104(3):246-250. PubMed ID: 30026253
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.
    Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, Hoeft S, Walscheid K, Lavric M, Foell D, Minden K.
    Rheumatology (Oxford); 2019 Jun 01; 58(6):975-986. PubMed ID: 30590748
    [Abstract] [Full Text] [Related]

  • 20. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
    Quartier P, Baptiste A, Despert V, Allain-Launay E, Koné-Paut I, Belot A, Kodjikian L, Monnet D, Weber M, Elie C, Bodaghi B, ADJUVITE Study Group.
    Ann Rheum Dis; 2018 Jul 01; 77(7):1003-1011. PubMed ID: 29275333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.